AbCellera Biologics Inc. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock
AbCellera Biologics Inc. (ABCL) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock of 63.26 million shares for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-21.
Discontinued › Income Statement
us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock · last filed 2023-02-21
- AbCellera Biologics Inc. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2020-06-30 was 81.23M shares.
- AbCellera Biologics Inc. incremental common shares attributable to dilutive effect of conversion of preferred stock for fiscal 2020 was 63.26M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 12 month |
|---|---|---|---|---|
| 2020-12-31 | 63.26M shares 10-K · filed 2023-02-21 | |||
| 2020-09-30 | 63.00M shares 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | 81.23M shares 10-Q · filed 2021-08-13 | 53.97M shares 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |